Literature DB >> 26246268

High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease.

Tetsuya Ishikawa1, Makoto Ayaori2, Harumi Uto-Kondo2, Takatomo Nakajima3, Makoto Mutoh3, Katsunori Ikewaki2.   

Abstract

BACKGROUND: We examined the clinical relevance of high-density lipoprotein cholesterol (HDL-C) efflux capacity from macrophage (cholesterol efflux capacity) as a predictor of atherosclerotic coronary artery disease (CAD) in comparison with that of conventional coronary and lipid risk variables in Japanese daily practice. METHODS AND
RESULTS: Fasting blood sampling, including 6 routinely measured dyslipidemia-related variables, was performed at the time of coronary angiography (CAG) or multi-slice coronary computed tomography (MSCT) between January 2011 and January 2013. CAD, defined as native coronary atherosclerosis stenosis >50% by CAG or MSCT, was identified in 182 patients (CAD group), but not in 72 patients (non-CAD group). Cholesterol efflux capacity, measured using a cell-based efflux system in (3)[H]-cholesterol-labeled J774 macrophages in apolipoprotein B-depleted plasma, was significantly impaired in the CAD group compared with the non-CAD group (0.86 ± 0.26 vs. 1.02 ± 0.38; p = 0.001). After adjusting 15 patient and dyslipidemia-related variables using a propensity score matching analysis produced 55 patients in each arm, cholesterol efflux capacity in the CAD group remained to be significant compared with the non-CAD group (0.83 ± 0.24 vs. 0.97 ± 0.36; p = 0.019). Stepwise logistic regression analysis using a backward method after the baseline adjustment showed that cholesterol efflux capacity (odds ratio [OR]: 0.23; 95% confidence interval [CI]: 0.056-0.91; p = 0.037) was the single predictor of CAD, while other variables including HDL-C (p = 0.088) and apolipoprotein (apo) A-I (p = 0.681) were removed owing to those insignificance. The area under the receiver operating characteristic curve after the baseline adjustment was 0.67 (95% CI: 0.51-0.73, p = 0.048 by Hosmer-Lemeshow goodness-of-fit statistics).
CONCLUSIONS: The present observational study conducted under daily clinical practice confirmed that cholesterol efflux capacity is a clinically relevant predictor of CAD among the conventional coronary risk factors and dyslipidemia-related variables.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; High-density lipoprotein cholesterol efflux capacity; Lipid disorder; Low-density lipoprotein cholesterol; Propensity score matching analysis

Mesh:

Substances:

Year:  2015        PMID: 26246268     DOI: 10.1016/j.atherosclerosis.2015.06.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

Review 1.  HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.

Authors:  Anish Bhatt; Anand Rohatgi
Journal:  Curr Atheroscler Rep       Date:  2016-01       Impact factor: 5.113

2.  Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.

Authors:  Bo Zheng; Shinya Goto; Regina Clementi; John Feaster; Danielle Duffy; Penelope Dalitz; Jolanta Airey; Serge Korjian; Michael A Tortorici; John Roberts; C Michael Gibson
Journal:  Clin Transl Sci       Date:  2022-08-07       Impact factor: 4.438

3.  Macrophage microRNA-150 promotes pathological angiogenesis as seen in age-related macular degeneration.

Authors:  Jonathan B Lin; Harsh V Moolani; Abdoulaye Sene; Rohini Sidhu; Pamela Kell; Joseph B Lin; Zhenyu Dong; Norimitsu Ban; Daniel S Ory; Rajendra S Apte
Journal:  JCI Insight       Date:  2018-04-05

Review 4.  HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics.

Authors:  Cecilia Vitali; Sumeet A Khetarpal; Daniel J Rader
Journal:  Curr Cardiol Rep       Date:  2017-11-04       Impact factor: 2.931

5.  Hepatic Overexpression of Endothelial Lipase Lowers High-Density Lipoprotein but Maintains Reverse Cholesterol Transport in Mice: Role of Scavenger Receptor Class B Type I/ATP-Binding Cassette Transporter A1-Dependent Pathways.

Authors:  Shunichi Takiguchi; Makoto Ayaori; Emi Yakushiji; Takafumi Nishida; Kazuhiro Nakaya; Makoto Sasaki; Maki Iizuka; Harumi Uto-Kondo; Yoshio Terao; Makiko Yogo; Tomohiro Komatsu; Masatsune Ogura; Katsunori Ikewaki
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05-10       Impact factor: 8.311

Review 6.  High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.

Authors:  Chengfeng Qiu; Xiang Zhao; Quan Zhou; Zhen Zhang
Journal:  Lipids Health Dis       Date:  2017-11-10       Impact factor: 3.876

Review 7.  Pharmacological Intervention to Modulate HDL: What Do We Target?

Authors:  Nicholas J Woudberg; Sarah Pedretti; Sandrine Lecour; Rainer Schulz; Nicolas Vuilleumier; Richard W James; Miguel A Frias
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

8.  The pleiotropic vasoprotective functions of high density lipoproteins (HDL).

Authors:  Guilaine Boyce; Emily Button; Sonja Soo; Cheryl Wellington
Journal:  J Biomed Res       Date:  2017-05-26

9.  Anti-Atherosclerotic Effect of a Polyphenol-Rich Ingredient, Oleactiv®, in a Hypercholesterolemia-Induced Golden Syrian Hamster Model.

Authors:  Cindy Romain; Antonio Piemontese; Simone Battista; Franco Bernini; Alice Ossoli; Arianna Strazzella; Sylvie Gaillet; Jean-Max Rouanet; Julien Cases; Ilaria Zanotti
Journal:  Nutrients       Date:  2018-10-15       Impact factor: 5.717

10.  High-Density Lipoprotein Cholesterol Efflux Capacity as a Novel Prognostic Surrogate for Coronary Artery Disease.

Authors:  Itaru Hisauchi; Tetsuya Ishikawa; Makoto Ayaori; Harumi Uto-Kondo; Yuri Koshikawa; Tomoaki Ukaji; Hidehiko Nakamura; Yukiko Mizutani; Isao Taguchi; Takatomo Nakajima; Makoto Mutoh; Katsunori Ikewaki
Journal:  J Atheroscler Thromb       Date:  2020-09-08       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.